;PMID: 10220498
;source_file_1302.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:46..120] = [t:46..120]
;2)section:[e:124..158] = [t:124..158]
;3)section:[e:162..257] = [t:162..257]
;4)sentence:[e:261..279] = [t:261..279]
;5)sentence:[e:280..338] = [t:280..338]
;6)sentence:[e:340..437] = [t:340..437]
;7)sentence:[e:438..575] = [t:438..575]
;8)sentence:[e:577..585] = [t:577..585]
;9)sentence:[e:586..693] = [t:586..693]
;10)sentence:[e:694..762] = [t:694..762]
;11)sentence:[e:763..876] = [t:763..876]
;12)sentence:[e:877..935] = [t:877..935]
;13)sentence:[e:936..1001] = [t:936..1001]
;14)sentence:[e:1002..1141] = [t:1002..1141]
;15)sentence:[e:1142..1150] = [t:1142..1150]
;16)sentence:[e:1151..1321] = [t:1151..1321]
;17)sentence:[e:1322..1421] = [t:1322..1421]
;18)sentence:[e:1422..1506] = [t:1422..1506]
;19)sentence:[e:1507..1622] = [t:1507..1622]
;20)sentence:[e:1623..1782] = [t:1623..1782]
;21)sentence:[e:1783..1986] = [t:1783..1986]
;22)sentence:[e:1988..2000] = [t:1988..2000]
;23)sentence:[e:2001..2121] = [t:2001..2121]
;24)section:[e:2125..2170] = [t:2125..2170]

;section 0 Span:0..41
;Gastroenterology  1999 May;116(5):1063-71
(SEC
  (FRAG (IN:[0..16] Gastroenterology) (CD:[18..22] 1999) (NNP:[23..26] May)
        (CD:[26..30] ;116) (-LRB-:[30..31] -LRB-) (CD:[31..32] 5)
        (-RRB-:[32..33] -RRB-) (::[33..34] :) (CD:[34..38] 1063) (::[38..39] -)
        (CD:[39..41] 71)))

;sentence 1 Span:46..120
;Association of K-ras mutations with p16 methylation in human colon cancer.
;[61..66]:gene-rna:"K-ras"
;[82..85]:gene-rna:"p16"
;[107..119]:malignancy-type:"colon cancer"
(SENT
  (NP-HLN
    (NP (NN:[46..57] Association))
    (PP (IN:[58..60] of)
      (NP (NN:[61..66] K-ras) (NNS:[67..76] mutations)))
    (PP (IN:[77..81] with)
      (NP (NN:[82..85] p16) (NN:[86..97] methylation)))
    (PP (IN:[98..100] in)
      (NP (JJ:[101..106] human)
         (NN:[107..112] colon) (NN:[113..119] cancer)))
    (.:[119..120] .)))

;section 2 Span:124..158
;Guan RJ, Fu Y, Holt PR, Pardee AB.
(SEC
  (FRAG (NNP:[124..128] Guan) (NNP:[129..131] RJ) (,:[131..132] ,)
        (NNP:[133..135] Fu) (NNP:[136..137] Y) (,:[137..138] ,)
        (NNP:[139..143] Holt) (NNP:[144..146] PR) (,:[146..147] ,)
        (NNP:[148..154] Pardee) (NN:[155..157] AB) (.:[157..158] .)))

;section 3 Span:162..257
;Division of Gastroenterology, Brigham & Women's Hospital, Boston, USA. 
;rguan@mbcrr.harvard.edu
(SEC
  (FRAG (NNP:[162..170] Division) (IN:[171..173] of)
        (NNP:[174..190] Gastroenterology) (,:[190..191] ,)
        (NNP:[192..199] Brigham) (CC:[200..201] &) (NNP:[202..207] Women)
        (POS:[207..209] 's) (NNP:[210..218] Hospital) (,:[218..219] ,)
        (NNP:[220..226] Boston) (,:[226..227] ,) (NNP:[228..231] USA)
        (.:[231..232] .) ('':[234..245] rguan@mbcrr) (VBD:[245..253] .harvard)
        (.:[253..257] .edu)))

;sentence 4 Span:261..279
;BACKGROUND & AIMS:
(SENT
  (NP (NN:[261..271] BACKGROUND) (CC:[272..273] &) (NNS:[274..278] AIMS)
      (::[278..279] :)))

;sentence 5 Span:280..338
;K-ras mutations are early genetic changes in colon cancer.
;[280..285]:gene-rna:"K-ras"
;[325..337]:malignancy-type:"colon cancer"
(SENT
  (S
    (NP-SBJ (NN:[280..285] K-ras) (NNS:[286..295] mutations))
    (VP (VBP:[296..299] are)
      (NP-PRD
        (NP (JJ:[300..305] early) (JJ:[306..313] genetic)
            (NNS:[314..321] changes))
        (PP (IN:[322..324] in)
          (NP (NN:[325..330] colon) (NN:[331..337] cancer)))))
    (.:[337..338] .)))

;sentence 6 Span:340..437
;p16, a tumor-suppressor gene, is inactivated in neoplasms by mutation,
;deletion,  or methylation.
;[340..343]:gene-rna:"p16"
;[411..419]:variation-type:"deletion"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[340..343] p16))
      (,:[343..344] ,)
      (NP (DT:[345..346] a)
        (NML (NN:[347..352] tumor) (HYPH:[352..353] -)
             (NN:[353..363] suppressor))
        (NN:[364..368] gene)))
    (,:[368..369] ,)
    (VP (VBZ:[370..372] is)
      (VP (VBN:[373..384] inactivated)
        (NP-1 (-NONE-:[384..384] *))
        (PP (IN:[385..387] in)
          (NP (NNS:[388..397] neoplasms)))
        (PP (IN:[398..400] by)
          (NP-LGS (NN:[401..409] mutation) (,:[409..410] ,)
                  (NN:[411..419] deletion) (,:[419..420] ,) (CC:[422..424] or)
                  (NN:[425..436] methylation)))))
    (.:[436..437] .)))

;sentence 7 Span:438..575
;The aims of this study were to determine p16 methylation status  and its
;possible association with K-ras mutations in human colon cancer.
;[479..482]:gene-rna:"p16"
;[537..542]:gene-rna:"K-ras"
;[562..574]:malignancy-type:"colon cancer"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[438..441] The) (NNS:[442..446] aims))
      (PP (IN:[447..449] of)
        (NP (DT:[450..454] this) (NN:[455..460] study))))
    (VP (VBD:[461..465] were)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[465..465] *))
        (VP (TO:[466..468] to)
          (VP (VB:[469..478] determine)
            (NP
              (NP (NN:[479..482] p16) (NN:[483..494] methylation)
                  (NN:[495..501] status))
              (CC:[503..506] and)
              (NP
                (NP (PRP$:[507..510] its) (JJ:[511..519] possible)
                    (NN:[520..531] association))
                (PP (IN:[532..536] with)
                  (NP
                    (NP (NN:[537..542] K-ras) (NNS:[543..552] mutations))
                    (PP (IN:[553..555] in)
                      (NP (JJ:[556..561] human)
                         (NN:[562..567] colon) (NN:[568..574] cancer)))))))))))
    (.:[574..575] .)))

;sentence 8 Span:577..585
;METHODS:
(SENT
  (NP (NNS:[577..584] METHODS) (::[584..585] :)))

;sentence 9 Span:586..693
;DNA isolated from 8 colon cancer cell lines and 41 microdissected human 
;colon tissue samples was analyzed.
;[606..618]:malignancy-type:"colon cancer"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[586..589] DNA))
      (VP (VBN:[590..598] isolated)
        (NP (-NONE-:[598..598] *))
        (PP (IN:[599..603] from)
          (NP
            (NP (CD:[604..605] 8)
              (NML (NN:[606..611] colon) (NN:[612..618] cancer))
              (NN:[619..623] cell) (NNS:[624..629] lines))
            (CC:[630..633] and)
            (NP (CD:[634..636] 41) (VBN:[637..651] microdissected)
              (NML (JJ:[652..657] human) (NN:[659..664] colon)
                   (NN:[665..671] tissue))
              (NNS:[672..679] samples))))))
    (VP (VBD:[680..683] was)
      (VP (VBN:[684..692] analyzed)
        (NP-1 (-NONE-:[692..692] *))))
    (.:[692..693] .)))

;sentence 10 Span:694..762
;p16 methylation status was determined using  two analytical methods.
;[694..697]:gene-rna:"p16"
(SENT
  (S
    (NP-SBJ-1 (NN:[694..697] p16) (NN:[698..709] methylation)
              (NN:[710..716] status))
    (VP (VBD:[717..720] was)
      (VP (VBN:[721..731] determined)
        (NP-1 (-NONE-:[731..731] *))
        (S-MNR
          (NP-SBJ (-NONE-:[731..731] *))
          (VP (VBG:[732..737] using)
            (NP (CD:[739..742] two) (JJ:[743..753] analytical)
                (NNS:[754..761] methods))))))
    (.:[761..762] .)))

;sentence 11 Span:763..876
;The level of p16 expression was determined by  reverse-transcription
;polymerase chain reaction and Northern blot.
;[776..779]:gene-rna:"p16"
;[832..842]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[763..766] The) (NN:[767..772] level))
      (PP (IN:[773..775] of)
        (NP (NN:[776..779] p16) (NN:[780..790] expression))))
    (VP (VBD:[791..794] was)
      (VP (VBN:[795..805] determined)
        (NP-1 (-NONE-:[805..805] *))
        (PP-MNR (IN:[806..808] by)
          (NP
            (NP
              (NML (NN:[810..817] reverse) (HYPH:[817..818] -)
                   (NN:[818..831] transcription))
              (NN:[832..842] polymerase) (NN:[843..848] chain)
               (NN:[849..857] reaction))
            (CC:[858..861] and)
            (NP (JJ:[862..870] Northern) (NN:[871..875] blot))))))
    (.:[875..876] .)))

;sentence 12 Span:877..935
;K-ras  mutations were determined by DNA sequence analysis.
;[877..882]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1 (NN:[877..882] K-ras) (NNS:[884..893] mutations))
    (VP (VBD:[894..898] were)
      (VP (VBN:[899..909] determined)
        (NP-1 (-NONE-:[909..909] *))
        (PP (IN:[910..912] by)
          (NP (NN:[913..916] DNA) (NN:[917..925] sequence)
              (NN:[926..934] analysis)))))
    (.:[934..935] .)))

;sentence 13 Span:936..1001
;The DNA methyltransferase  activity was determined by microassay.
;[944..961]:gene-protein:"methyltransferase"
(SENT
  (S
    (NP-SBJ-1 (DT:[936..939] The) (NN:[940..943] DNA)
              (NN:[944..961] methyltransferase) (NN:[963..971] activity))
    (VP (VBD:[972..975] was)
      (VP (VBN:[976..986] determined)
        (NP-1 (-NONE-:[986..986] *))
        (PP-MNR (IN:[987..989] by)
          (NP (NN:[990..1000] microassay)))))
    (.:[1000..1001] .)))

;sentence 14 Span:1002..1141
;Parental and K-ras-transformed IEC-18  cells were used to determine the
;potential association between K-ras mutations  and p16 methylation.
;[1015..1020]:gene-rna:"K-ras"
;[1104..1109]:gene-rna:"K-ras"
;[1125..1128]:gene-rna:"p16"
(SENT
  (S
    (NP-SBJ-2
      (NP (JJ:[1002..1010] Parental)
        (NML-1 (-NONE-:[1010..1010] *P*)))
      (CC:[1011..1014] and)
      (NP
        (ADJP (NN:[1015..1020] K-ras) (HYPH:[1020..1021] -)
              (VBN:[1021..1032] transformed))
        (NML-1 (NN:[1033..1039] IEC-18) (NNS:[1041..1046] cells))))
    (VP (VBD:[1047..1051] were)
      (VP (VBN:[1052..1056] used)
        (NP-2 (-NONE-:[1056..1056] *))
        (S-ADV
          (NP-SBJ (-NONE-:[1056..1056] *))
          (VP (TO:[1057..1059] to)
            (VP (VB:[1060..1069] determine)
              (NP
                (NP (DT:[1070..1073] the) (JJ:[1074..1083] potential)
                    (NN:[1084..1095] association))
                (PP (IN:[1096..1103] between)
                  (NP
                    (NP (NN:[1104..1109] K-ras) (NNS:[1110..1119] mutations))
                    (CC:[1121..1124] and)
                    (NP (NN:[1125..1128] p16) (NN:[1129..1140] methylation))))))))))
    (.:[1140..1141] .)))

;sentence 15 Span:1142..1150
;RESULTS:
(SENT
  (NP (NNS:[1142..1149] RESULTS) (::[1149..1150] :)))

;sentence 16 Span:1151..1321
;Methylated p16 was found in 100% of colon cancer  cell lines, 55% of colon
;cancers, 54% of adenomas, and 25% of transitional  mucosa but not in normal
;colonic epithelium.
;[1162..1165]:gene-rna:"p16"
;[1187..1199]:malignancy-type:"colon cancer"
;[1220..1233]:malignancy-type:"colon cancers"
;[1242..1250]:malignancy-type:"adenomas"
(SENT
  (S
    (NP-SBJ-1 (VBN:[1151..1161] Methylated) (NN:[1162..1165] p16))
    (VP (VBD:[1166..1169] was)
      (VP
        (VP (VBN:[1170..1175] found)
          (NP-1 (-NONE-:[1175..1175] *))
          (PP=2 (IN:[1176..1178] in)
            (NP
              (NP
                (NP (CD:[1179..1182] 100) (NN:[1182..1183] %))
                (PP (IN:[1184..1186] of)
                  (NP
                    (NML (NN:[1187..1192] colon) (NN:[1193..1199] cancer))
                    (NN:[1201..1205] cell) (NNS:[1206..1211] lines))))
              (,:[1211..1212] ,)
              (NP
                (NP (CD:[1213..1215] 55) (NN:[1215..1216] %))
                (PP (IN:[1217..1219] of)
                  (NP (NN:[1220..1225] colon) (NNS:[1226..1233] cancers))))
              (,:[1233..1234] ,)
              (NP
                (NP (CD:[1235..1237] 54) (NN:[1237..1238] %))
                (PP (IN:[1239..1241] of)
                  (NP (NNS:[1242..1250] adenomas))))
              (,:[1250..1251] ,) (CC:[1252..1255] and)
              (NP
                (NP (CD:[1256..1258] 25) (NN:[1258..1259] %))
                (PP (IN:[1260..1262] of)
                  (NP (JJ:[1263..1275] transitional) (NN:[1277..1283] mucosa)))))))
        (CC:[1284..1287] but)
        (VP (RB:[1288..1291] not)
          (PP=2 (IN:[1292..1294] in)
            (NP (JJ:[1295..1301] normal) (JJ:[1302..1309] colonic)
                (NN:[1310..1320] epithelium))))))
    (.:[1320..1321] .)))

;sentence 17 Span:1322..1421
;Forty-five percent of cancers and  38% of adenomas showed both K-ras
;mutations and p16 methylation.
;[1364..1372]:malignancy-type:"adenomas"
;[1385..1390]:gene-rna:"K-ras"
;[1405..1408]:gene-rna:"p16"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (CD:[1322..1332] Forty-five) (NN:[1333..1340] percent))
        (PP (IN:[1341..1343] of)
          (NP (NNS:[1344..1351] cancers))))
      (CC:[1352..1355] and)
      (NP
        (NP (CD:[1357..1359] 38) (NN:[1359..1360] %))
        (PP (IN:[1361..1363] of)
          (NP (NNS:[1364..1372] adenomas)))))
    (VP (VBD:[1373..1379] showed)
      (NP (CC:[1380..1384] both)
        (NP (NN:[1385..1390] K-ras) (NNS:[1391..1400] mutations))
        (CC:[1401..1404] and)
        (NP (CD:[1405..1408] p16) (NN:[1409..1420] methylation))))
    (.:[1420..1421] .)))

;sentence 18 Span:1422..1506
;Of 11 cancers  and adenomas with K-ras mutation, 10 specimens showed
;methylated p16.
;[1441..1449]:malignancy-type:"adenomas"
;[1455..1460]:gene-rna:"K-ras"
;[1502..1505]:gene-rna:"p16"
(SENT
  (S
    (PP-TPC-1 (IN:[1422..1424] Of)
      (NP
        (NP (CD:[1425..1427] 11) (NNS:[1428..1435] cancers))
        (CC:[1437..1440] and)
        (NP
          (NP (NNS:[1441..1449] adenomas))
          (PP (IN:[1450..1454] with)
            (NP (NN:[1455..1460] K-ras) (NN:[1461..1469] mutation))))))
    (,:[1469..1470] ,)
    (NP-SBJ
      (NP (CD:[1471..1473] 10) (NNS:[1474..1483] specimens))
      (PP-1 (-NONE-:[1483..1483] *T*)))
    (VP (VBD:[1484..1490] showed)
      (NP (VBN:[1491..1501] methylated) (NN:[1502..1505] p16)))
    (.:[1505..1506] .)))

;sentence 19 Span:1507..1622
;In  contrast, of 13 adenomas and cancers with wild-type K-ras, only 3
;specimens  showed methylated p16 (P = 0.001).
;[1527..1535]:malignancy-type:"adenomas"
;[1563..1568]:gene-rna:"K-ras"
(SENT
  (S
    (PP (IN:[1507..1509] In)
      (NP (NN:[1511..1519] contrast)))
    (,:[1519..1520] ,)
    (PP-TPC-1 (IN:[1521..1523] of)
      (NP
        (NP (CD:[1524..1526] 13) (NNS:[1527..1535] adenomas)
            (CC:[1536..1539] and) (NNS:[1540..1547] cancers))
        (PP (IN:[1548..1552] with)
          (NP
            (NML (JJ:[1553..1557] wild) (HYPH:[1557..1558] -)
                 (NN:[1558..1562] type))
            (NN:[1563..1568] K-ras)))))
    (,:[1568..1569] ,)
    (NP-SBJ
      (NP (RB:[1570..1574] only) (CD:[1575..1576] 3)
          (NNS:[1577..1586] specimens))
      (PP-1 (-NONE-:[1586..1586] *T*)))
    (VP (VBD:[1588..1594] showed)
      (NP (VBN:[1595..1605] methylated) (NN:[1606..1609] p16))
      (PRN (-LRB-:[1610..1611] -LRB-)
        (S
          (NP-SBJ (NN:[1611..1612] P))
          (VP (SYM:[1613..1614] =)
            (NP (CD:[1615..1620] 0.001))))
        (-RRB-:[1620..1621] -RRB-)))
    (.:[1621..1622] .)))

;sentence 20 Span:1623..1782
;Stable transformation of IEC-18 cells with  K-ras increased the DNA
;methyltransferase activity, methylated the p16 gene, and  suppressed the
;expression of p16.
;[1667..1672]:gene-rna:"K-ras"
;[1691..1708]:gene-protein:"methyltransferase"
;[1734..1737]:gene-rna:"p16"
;[1778..1781]:gene-rna:"p16"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1623..1629] Stable) (NN:[1630..1644] transformation))
      (PP (IN:[1645..1647] of)
        (NP
          (NP (NN:[1648..1654] IEC-18) (NNS:[1655..1660] cells))
          (PP (IN:[1661..1665] with)
            (NP (NN:[1667..1672] K-ras))))))
    (VP
      (VP (VBD:[1673..1682] increased)
        (NP (DT:[1683..1686] the) (NN:[1687..1690] DNA)
            (NN:[1691..1708] methyltransferase) (NN:[1709..1717] activity)))
      (,:[1717..1718] ,)
      (VP (VBD:[1719..1729] methylated)
        (NP (DT:[1730..1733] the) (NN:[1734..1737] p16) (NN:[1738..1742] gene)))
      (,:[1742..1743] ,) (CC:[1744..1747] and)
      (VP (VBD:[1749..1759] suppressed)
        (NP
          (NP (DT:[1760..1763] the) (NN:[1764..1774] expression))
          (PP (IN:[1775..1777] of)
            (NP (NN:[1778..1781] p16))))))
    (.:[1781..1782] .)))

;sentence 21 Span:1783..1986
;Treatment with a DNA methylation inhibitor  (azadeoxycytidine) resulted in
;reexpression of p16 in K-ras-transformed IEC-18  cells, suggesting that the
;expression of p16 was suppressed by DNA methylation.
;[1874..1877]:gene-rna:"p16"
;[1881..1886]:gene-rna:"K-ras"
;[1948..1951]:gene-rna:"p16"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1783..1792] Treatment))
      (PP (IN:[1793..1797] with)
        (NP (DT:[1798..1799] a) (NN:[1800..1803] DNA)
            (NN:[1804..1815] methylation) (NN:[1816..1825] inhibitor)
          (PRN (-LRB-:[1827..1828] -LRB-)
            (NP (NN:[1828..1844] azadeoxycytidine))
            (-RRB-:[1844..1845] -RRB-)))))
    (VP (VBD:[1846..1854] resulted)
      (PP-CLR (IN:[1855..1857] in)
        (NP
          (NP (NN:[1858..1870] reexpression))
          (PP (IN:[1871..1873] of)
            (NP (NN:[1874..1877] p16)))))
      (PP-LOC (IN:[1878..1880] in)
        (NP
          (ADJP (NN:[1881..1886] K-ras) (HYPH:[1886..1887] -)
                (VBN:[1887..1898] transformed))
          (NN:[1899..1905] IEC-18) (NNS:[1907..1912] cells)))
      (,:[1912..1913] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1913..1913] *))
        (VP (VBG:[1914..1924] suggesting)
          (SBAR (IN:[1925..1929] that)
            (S
              (NP-SBJ-1
                (NP (DT:[1930..1933] the) (NN:[1934..1944] expression))
                (PP (IN:[1945..1947] of)
                  (NP (NN:[1948..1951] p16))))
              (VP (VBD:[1952..1955] was)
                (VP (VBN:[1956..1966] suppressed)
                  (NP-1 (-NONE-:[1966..1966] *))
                  (PP (IN:[1967..1969] by)
                    (NP-LGS (NN:[1970..1973] DNA) (NN:[1974..1985] methylation))))))))))
    (.:[1985..1986] .)))

;sentence 22 Span:1988..2000
;CONCLUSIONS:
(SENT
  (NP (NNS:[1988..1999] CONCLUSIONS) (::[1999..2000] :)))

;sentence 23 Span:2001..2121
;p16 methylation occurs frequently in human colonic adenomas and  cancers and
;is closely associated with K-ras mutations.
;[2001..2004]:gene-rna:"p16"
;[2044..2060]:malignancy-type:"colonic adenomas"
;[2044..2051]...[2066..2073]:malignancy-type:"colonic"..."cancers"
;[2105..2110]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-2 (NN:[2001..2004] p16) (NN:[2005..2016] methylation))
    (VP
      (VP (VBZ:[2017..2023] occurs)
        (ADVP-TMP (RB:[2024..2034] frequently))
        (PP (IN:[2035..2037] in)
          (NP
            (NP
              (ADJP-1 (JJ:[2038..2043] human) (JJ:[2044..2051] colonic))
              (NNS:[2052..2060] adenomas))
            (CC:[2061..2064] and)
            (NP
              (ADJP-1 (-NONE-:[2064..2064] *P*))
              (NNS:[2066..2073] cancers)))))
      (CC:[2074..2077] and)
      (VP (VBZ:[2078..2080] is)
        (ADVP (RB:[2081..2088] closely))
        (VP (VBN:[2089..2099] associated)
          (NP-2 (-NONE-:[2099..2099] *))
          (PP-CLR (IN:[2100..2104] with)
            (NP (NN:[2105..2110] K-ras) (NNS:[2111..2120] mutations))))))
    (.:[2120..2121] .)))

;section 24 Span:2125..2170
;PMID: 10220498 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2125..2129] PMID) (::[2129..2130] :) (CD:[2131..2139] 10220498)
        (NN:[2140..2141] -LSB-) (NNP:[2141..2147] PubMed) (::[2148..2149] -)
        (NN:[2150..2157] indexed) (IN:[2158..2161] for)
        (NNP:[2162..2170] MEDLINE-RSB-)))